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Background: Chronic musculoskeletal pain is common and has been increasingly managed by opioid medications,
of which the long-term efficacy is unknown. Furthermore, there is evidence that long-term use of opioids is
associated with reduced pain control, declining physical function and quality of life, and could hinder the goals of
integrated pain management. Electroacupuncture (EA) has been shown to be effective in reducing postoperative
opioid consumption. Limited evidence suggests that acupuncture could assist patients with chronic pain to reduce
their requirements for opioids.
The proposed research aims to assess if EA is an effective adjunct therapy to standard pain and medication
management in reducing opioids use by patients with chronic musculoskeletal pain.
Methods: In this multicentre, randomised, sham-acupuncture controlled, three-arm clinical trial, 316 patients
regularly taking opioids for pain control and meeting the defined selection criteria will be recruited from pain
management centres and clinics of primary care providers in Victoria, Australia. After a four-week run-in period, the
participants are randomly assigned to one of three treatment groups to receive EA, sham EA or no-EA with a ratio
of 2:1:1. All participants receive routine pain medication management delivered and supervised by the trial medical
doctors. Twelve sessions of semi-structured EA or sham EA treatment are delivered over 10 weeks. Upon
completion of the acupuncture treatment period, there is a 12-week follow-up. In total, participants are involved in
the trial for 26 weeks. Outcome measures of opioid and non-opioid medication consumption, pain scores and
opioid-related adverse events are documented throughout the study. Quality of life, depression, function, and
attitude to pain medications are also assessed.
Discussion: This randomised controlled trial will determine whether EA is of significant clinical value in assisting
the management of debilitating chronic pain by reducing opioids consumption and their associated adverse
events, as well as improving the quality of life for those with chronic pain. Such an outcome will provide the
rationale for including EA into multidisciplinary programmes for effective management of chronic musculoskeletal
pain.
Trial registration: Australian New Zealand Clinical Trial Registry (ACTRN12609000676213)
http://www.anzctr.org.au/trial_view.aspx?ID=308008
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Opioid medications for chronic pain
One in five Australians suffers from chronic pain, with
the majority having chronic musculoskeletal pain (CMP)
[1]. Chronic pain is the third most costly health condi-
tion and costs the Australian government $4.7 billion
dollars each year [2].
Due to the difficulty in managing CMP, morphine and
other strong opioids have been increasingly used. Opioid
medication (OM) prescriptions for CMP doubled from
8% to 16% in the United States of America between
1980 and 2000 [3]. In Australia, 13% of chronic pain
patients were on some type of opioids in a 1999 survey
[4]. From 1999 to 2005, the total OM consumption in
Australia had increased by more than eight times for
oxycodone (to 38.9 mg per capita), 40 times for hydro-
morphone and five times for fentanyl [5].
The effectiveness of OM for CMP is debatable [6].
Three recent systematic reviews concluded that OM
reduced pain by 30% in the short term. However, its
long-term efficacy is unknown [7-9]. A follow-up study
of patients who were still on OM 10 years after comple-
tion of a multidisciplinary pain management programme
reported that those patients had poorer quality of life,
were more depressed, and adopted passive strategies for
pain management, indicating that opioids were ineffect-
ive for this group [10]. Furthermore, opioids are asso-
ciated with a high rate of adverse events (AEs), such as
drowsiness, nausea, vomiting, constipation, dry mouth,
dose escalation and/or tolerance, hyperalgesia and de-
pendence when used for treating chronic pain [11].
Part of integrated pain management is to assist
patients in reducing OM use through pain medication
management (PMM), including education about pain
and adjustment of pain medication, and is usually given
by clinicians and nurses. However, there are very few
other options. There is an urgent need to identify a ther-
apy that could effectively assist the reduction of OM.Electroacupuncture
Acupuncture, one of several non-pharmacological ther-
apies for managing pain, has been found to stimulate the
releases of endogenous opioid peptides in animals and
humans [12-14]. A recent human study using positron
emission tomography found that patients with fibro-
myalgia displayed reduced binding potential of opioids
in comparison to pain-free controls [15]. In addition,
nine sessions of acupuncture increased opioid bindingpotential in certain brain regions of a similar group of
patients significantly more than sham acupuncture [16].
Combined with the increased release of endogenous opi-
oid peptides upon acupuncture, this increased binding
effect might in turn enhance the efficiency of OM and
decrease the amount required for functional improve-
ment and pain relief.
When used in postoperative pain, electroacupuncture
(EA) - acupuncture combined with electrical stimulation
- reduced the use of postoperative morphine by more
than 60% and was 30% better than sham procedures. It
also reduced the severity and incidence of OM-related
side effects [17,18]. Our pilot study in 35 patients with
chronic pain also showed that EA reduced OM con-
sumption by 39% in comparison with a 25% reduction in
the sham EA group, with 90% patient satisfaction [19].
Aims
In this multicentre, randomised, sham-acupuncture con-
trolled, three-arm clinical trial, we will evaluate the effect
of EA as an adjunct therapy to PMM on OM consump-
tion by patients with CMP. The primary hypothesis is
that EA reduces OM consumption significantly more
than sham EA. The secondary hypotheses are that:
1. the proportion of participants who experience 50%
or more OM reduction is significantly higher in the
EA group than that in the sham EA group;
2. EA reduces OM-related AEs significantly more than
sham EA;
3. EA combined with PMM is significantly better than
PMM alone in reducing OM usage and AEs;
4. EA reduces the intensity of pain and improves
function significantly better than sham EA;
5. participants having a strong self-reliant attitude to
pain consume significantly less OM than those
relying on medications for pain relief.
Methods
The trial is being conducted between July 2009 and
December 2012, and has been approved by the Human
Research Ethics Committees of Melbourne Health
(2009.033), Alfred Health (80.09) and the RMIT Uni-
versity (06/09) to be conducted at the Pain Services of
the Royal Melbourne Hospital, the Caulfield Pain Man-
agement and Research Centre of the Caulfield Hos-
pital, the Sunshine Hospital, and various sites in
Melbourne and Geelong. It has been registered with
Xue et al. Trials 2012, 13:169 Page 3 of 8
http://www.trialsjournal.com/content/13/1/169the Australian New Zealand Clinical Trial Registry
(ACTRN12609000676213).
The design of the trial follows the CONSORT state-
ment [20] and the Initiative on Methods, Measurements,
and Pain Assessment in Clinical Trial for chronic pain
[21]. The procedure of the trial is presented in Figure 1.
Power and sample size calculation
Using sample means from baseline and the end of the
treatment phase of the OM consumption data from our
pilot study [19], we estimate that a total sample size of
316 will provide 80% power using a 1% level of signifi-
cance to detect an effect size estimate of 0.48 between
the EA and sham EA groups. Because intention-to-treat
analysis will be used, no additional participants are
required. We plan to recruit 316 participants in total. A
dropout rate of 20% is considered to be within the nor-
mal range.
Participant recruitment
Patients attending three major pain management centres
are notified of the trial by leaflets displayed at the cen-
tres or referred by the staff at the pain clinics. Informa-
tion about the trial is also disseminated through health
professionals’ networks, including Chinese medicine,
chiropractic, general practice, massage therapy, naturop-
athy, osteopathy, pharmacy and physiotherapy and
through networks for patients with chronic pain, such as
Chronic Pain Australia. Interested patients complete a
form to express their intention to participate. A re-
searcher from the trial administration centre (RMIT
University) then conducts an initial screening, which is
followed by a face-to-face interview with a researcherFigure 1 A flow chart of the trial process.and assessment by a medical doctor (MD) at one of the
hospital sites prior to randomisation.
Inclusion criteria
Participants meeting the following criteria are included:
1. age between 18 and 85 years at entry
2. confident in conversational and reading English
3. suffering from CMP, regardless of the locations of
pain
4. have taken OM regularly for more than two months
without dose limitation.
Exclusion criteria
Participants having one or more of the following criteria
are excluded:
1. active abuse of OM as judged by an MD
2. severely depressed with suicidal tendency as judged
by MDs
3. unstable heart condition, pregnancy or intent to
become pregnant, breastfeeding women, epilepsy,
brain tumour, current cancer, haemophilia or
wearing cardiac pacemakers
4. no general practitioner available for liaison
5. acupuncture treatment in the last 12 months
6. unwilling to reduce OM.
Prior to the eligibility assessment, all participants are
provided with adequate information about the study,
written in plain English, and all questions are answered
to their level of satisfaction before informed consent is
signed.
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After a four-week run-in period, participants who meet
all selection criteria are randomly allocated into one of
the three groups, namely EA, sham EA or no-EA with a
2:1:1 ratio. An automated telephone randomisation ser-
vice provided by the National Health and Medical
Research Council Clinical Trial Centre at the University
of Sydney is used. Before the commencement of the first
acupuncture session, the treating acupuncturist dials a
toll-free number and enters the identification codes of
the trial, the acupuncturist and the site, and the baseline
OM weekly dose (morphine equivalent). The participant
is then randomly allocated to one of the three groups
according to a computer-generated randomisation se-
quence. The acupuncturist records the allocation in a
secure and separate file. The computer-generated ran-
domisation uses stratified permuted blocks to ensure
that an equal ratio of participants in EA and sham EA
groups in each centre is assigned to each acupuncturist;
and to ensure that an equal number of participants con-
suming high or low dose of OM is assigned to each
group. The cut-off OM dose for high or low consump-
tion is 560 mg (morphine equivalents) per week, decided
upon by pain specialists on the team based on our pilot
study and other published studies reporting average OM
consumption by patients with chronic pain [22,23].
Three quarters of the participants are in either the EA
or sham EA group and are blinded; one quarter of the
participants are in the no-EA group and are be blinded.
The success of blinding of the two acupuncture groups
is assessed. Details are presented in Assessment of effi-
cacy below.
The acupuncturists and MDs are not involved in out-
come assessments. Blinded assessors are required to
conduct outcome assessments, collect Medication and
Pain Diaries, and check any missing data. The trial data
are entered by research assistants and analysed by a sta-
tistician. Except for the acupuncturists, all of the above
will be are blinded to participant allocation. Professional
statistical assistance is also sought to double check the
data analysis.
Trial procedure
As shown in Figure 1, during the initial visit participants
provide personal and demographic details and pain his-
tory. A four-week run-in period (first to fourth week)
follows. During this time, the general practitioners of the
participants are notified. Their assistance in prescribing
OM and not introducing non-essential therapy during
the trial is sought. Participants are also seen by MDs to
confirm eligibility. All participants receive PMM, which
is provided by MDs in the fifth week. Participants then
receive EA, sham EA or no-EA for 10 weeks. Those who
are allocated to the no-EA PMM alone group are giventhe opportunity to have EA treatment at the end of the
10-week treatment period. Participants in the EA and
sham EA groups are followed-up for three months.
Electroacupuncture interventions
The selection of acupuncture points is semi-structured.
Unilateral Shousanli LI10 and Hegu LI4 (on the forearm
and hand), and Zusanli ST36 and Fenglong ST40 (on
the leg) will be used for EA. Up to eight supplementary
acupuncture points will be chosen according to the ad-
verse effects of OM that participants experience during
that week. These points are manually needled. In total,
up to 12 needles are used for each session. Disposable
acupuncture needles of 0.25 mm diameter and 30 or
40 mm length (Hwato, Suzhou Medical Instrument Fac-
tory, China) are used.
The real and sham acupuncture procedures follow
those described in our previous study [19] and the Stan-
dards for Reporting Interventions in Controlled Trials of
Acupuncture [24]. Briefly, in the EA group, after needle
insertion and de qi sensation is produced, described as a
numb, distended and aching sensation, a battery oper-
ated electroacupuncture instrument (Model E600 HAN
Multi-Purpose Digital Electronic Acupunctoscope, man-
ufactured by Tens Plus Industrial Company, Hong
Kong) is connected to the handles of four needles in the
main acupuncture points in the extremities to deliver
electrical stimulation for 20 minutes. Electrical stimuli
will be delivered at an alternating frequency of 2 and
100 Hz every 3 seconds. The intensity of stimulation is
strong but comfortable, and adjusted once during the
treatment.
For sham EA, a set of sham points are developed to
match each real point. Needles are shallowly inserted
into the sham points without manipulation. A manufac-
ture modified non-functioning EA stimulator showing a
continuously flashing light and emitting a beeping sound
is connected to the end of the four needles via wires,
and placed on a table within the participant’s sight. De
qi sensation is not intended. We have used this proced-
ure previously, and participants could not tell EA from
sham EA [19].
The treatment will be given twice a week for four
weeks followed by once a week for two weeks then once
every two weeks for four weeks. In total, 12 sessions
should be delivered within 10 weeks. Participants com-
pleting less than 50% of the treatment are considered as
non-compliant. Their data will be treated as missing
data.
Pain medication management
PMM is an integral part of pain management in multi-
disciplinary clinics. In this trial, PMM consists of patient
education about pain and pain medications, and advice
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Information Brochure has been developed to standardise
PMM across all centres. In the fifth week, MDs explains
to participants the impact of chronic pain, and the po-
tential problems associated with OMs. OM reduction
schedules are developed and explained to each partici-
pant at the interview. The schedule is flexible and indi-
vidually tailored. It includes instructions for which type
of OM to reduce first, how much and when, the alterna-
tive medications and what to do if pain increases. In
general, short-acting OMs are reduced first, then the
long-acting (slow-release) OMs. Participants are asked
to reduce their OM dosage by 30% in week 8, 50% by
week 11 and 75% to 100% by Week 14. Participants are
asked to reduce OM as long as their pain is not worse. If
increased pain causes distress or dysfunction, partici-
pants can increase their OM dose to the previous level
or take alternative non-opioid medications prescribed by
MDs. Clonidine may be prescribed for participants ex-
periencing opioid withdrawal symptoms as judged by
the MDs. The dosages of all pain relief medications are
recorded.
As part of PMM, during the 10-week treatment and
the three-month follow-up periods, a trained researcher
will make a phone call to all participants three times
during the treatment and once a month during the
follow-up period to remind participants of the OM re-
duction schedule. During the trial period, participants
are instructed to continue their routine therapies.Table 1 Outcome measures to be administered throughout th
Outcome measures Components measured
Questionnaires to assess outcomes of the treatment
Diary Pain OM use non-OM use
Beck Depression Inventory Mental status
SF-36v2 Quality of life
Roland Morris Disability Questionnaire Functionality
Short Opiate Withdrawal Scale Withdrawal symptoms
Survey of patients’ attitude Changes of attitudes
Chinese Medicine Chronic Pain Questionnaire Pain and non-pain signs and
Questionnaires to assess credibility, expectancy and attitude to acupun
Perception of EA treatment
Acupuncture Expectancy Scale
Knowledge of Acupuncture
Pain Medication Questionnaire
Elements of neuropathic pain
S-LANSS
OM: opioid medication; EA: electroacupuncture; SF-36v2: 36-item Short-Form Health
Symptoms and Signs; W: week.Therapists
EA is provided by registered acupuncturists with at least
three years of clinical experience. PMM is given by MDs
at the pain management centres. All therapists undergo
pre-trial training regarding the trial procedures. An Acu-
puncture Treatment Manual has been developed for
training acupuncturists; and the Pain and Medication
Management Information Brochure is used for training
MDs.
Co-interventions
Co-interventions are discouraged. Participants using
other therapies for CMP such as herbal medicine,
physiotherapy, chiropractic and osteopathy are required
to either discontinue them before entering into the trial
or maintain their use during the trial and record use in
their diaries.
Withdrawal
Participants who find their pain significantly worse or
cannot tolerate EA may terminate their involvement in
the study. They are assessed by one of the MDs with ad-
vice on alternative management strategies for their con-
dition. Their data will be treated as missing data.Assessment of efficacy
A list of outcome measurement tools and when they are
administered are listed in Table 1.e trial
Baseline Treatment period Follow-up period
W1 W5 W10 W14 W18 W22 W26
✓W1 to W4 ✓ ✓ ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓ ✓ ✓
symptoms ✓ ✓ ✓ ✓
cture or pain medications
✓(W6) ✓
✓(W5)
✓
✓
✓(W5)
Survey version 2; S-LANSS: self-report Leeds Assessment of Neuropathic
Xue et al. Trials 2012, 13:169 Page 6 of 8
http://www.trialsjournal.com/content/13/1/169Primary outcome measure
The primary outcome measure is the change in OM be-
tween baseline and the end of the treatment period. OM
usage is recorded daily in the Medication and Pain Diar-
ies during the run-in period (between the first and
fourth weeks), treatment period (between the 5th and
14th weeks) and follow-up period in the 18th, 22nd
and 26th weeks. To make meaningful comparisons on
medication use, the dosage of OM will be converted into
morphine equivalent dose for data analysis [25].
Secondary outcome measures
Secondary outcome measures assess pain; impact of pain
including function, quality of life and depression; con-
sumption of non-opioid medications; and participants’
attitude to pain. All instruments have been widely used
and demonstrated reliability and validity in the chronic
pain population.
The outcome measures are as follows:
1. Number of participants who achieve 50% OM
reduction at the end of the treatment and follow-up
periods.
2. Type, severity and incidence of OM-related
common AEs. Common AEs are somnolence,
mental clouding, nausea and constipation.
Uncommon AEs are fatigue, itching, adverse mood
changes and dry mouth. They are assessed using
visual analogues scale (0 = no symptom at all,
10 = very severe) to indicate the severity of these
events.
3. Consumption of non-opioid medications.
4. Pain intensity measured with visual analogue scale
(0 = no pain; 10 =worst pain possible) in the
Medication and Pain Diary.
5. Quality of life assessed with 36-item Short-Form
Health Survey version 2 (SF-36) [26].
6. Severity of depression assessed with the Beck
Depression Inventory [27].
7. The level of function assessed with the Roland
Morris Disabilities Questionnaire [28].
8. The presentation and severity of withdrawal
symptoms assessed with Short Opiate Withdrawal
Scale [29].
9. Participants’ attitude of pain assessed with Survey of
Patients’ Attitude [30].
10. Chinese Medicine Chronic Pain Questionnaire,
which we have developed to assess pain and non-
pain signs and symptoms.
To make meaningful comparisons of non-opioid medi-
cations usage, the dosage of such medications is calcu-
lated according to Medication Quantification Scale
Version III [31]. The Perception of EA TreatmentQuestionnaire [18] is given to the two acupuncture
groups to assess the success of blinding in the 6th and
14th weeks. We also use Self-reported Leeds Assessment
of Neuropathic Symptoms and Signs [32] to assess the
certainty of neuropathic component of the pain.
Assessment of safety and report of serious adverse
events
An AE record form is attached to the end of the Medi-
cation and Pain Diaries so that participants can record
any unexpected signs, symptoms and feelings during and
after the treatment period. Acupuncture-related AEs are
dizziness, fatigue, pain, bruising and infection. These will
be scored using six-point scales (0 = none, 1 =minimal,
2 =mild, 3 =moderate, 4 = severe, and 5 = extremely
severe). Participants are educated to differentiate AEs
that are acupuncture-related from those that are OM-
related. The former is usually short-lasting, whereas the
latter persists when OM is consumed. Similarly, the acu-
puncturists will be required to record any adverse reac-
tions during and after each treatment session. The
likelihood that serious AEs reported by participants and
acupuncturists are EA-related or OM-related will be
assessed by two team members (ZZ, RH). They also con-
sult, as appropriate, with the participant, MDs, and/or
acupuncturists. The result of the assessment is recorded.
Data storage and access
All participants’ files are kept in a coded order in secure
locked cabinets. Consent forms and personal information
are stored separately from study questionnaires. Data in
electronic files are de-identified and files are stored as
password protected intranet files at the trial administra-
tion centre. Only authorized research personnel have ac-
cess to hard and soft copies of the files. The information
is retained for 15 years. After that information will be
shredded and disposed of according to university proced-
ure. Only aggregated data will be presented in
publications.
Statistical analysis of the trial outcomes
The Statistical Program for Social Science (SPSS, the lat-
est version) is used for data analyses. Baseline categorical
data, demographic characteristics such as gender and
age category, and numerical data are analysed with χ2
tests and one-way analysis of variance, respectively, to
determine comparability of the three groups on these
variables.
Linear mixed models (for continuous outcome vari-
ables) and generalised estimating equations (for categor-
ical outcome variables) are used to examine the changes
over time in weekly dosage of OM, numbers and types
of OM-related AEs, severity of pain and Beck
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group differences in the numbers of dropouts and AEs.
Both intention-to-treat and per protocol analyses are
used. Data from participants who do not violate the
treatment protocols will be included in the per protocol
analysis. Missing data are dealt with using the last value
carried forward method. Missing Beck Depression In-
ventory and SF-36 data are dealt with according to the
relevant manual.
Apart from the effects of types of intervention, the in-
fluence on the outcomes of differences between centres
and therapists is also analysed. The relationship between
OM reduction and attitude to pain are explored.
Discussion
CMP is prevalent, with high socioeconomic impacts.
OMs have been increasingly prescribed for patients with
CMP both in Australia and worldwide. There is, how-
ever, no evidence supporting the long-term use of
opioids for patients with CMP. Furthermore, OM is
associated with severe AEs, which further impact on
patients’ quality of life. OM might be a hindrance that
prevents patients from taking part in more active man-
agement programmes. Effective treatments that reduce
OM consumption and related AEs are urgently needed
and will benefit both patients and society.
Our pilot study shows that EA, when combined with
PMM, is potentially effective in reducing OM usage by
patients with chronic non-cancer pain. It also demon-
strates the feasibility of a collaborative research involving
complementary health professionals, clinicians in pain
management, pain researchers and acupuncture research-
ers. Following the validated protocol, with an expanded
team of experts and researchers, the proposed study will
for the first time determine whether EA is of significant
clinical value in assisting the management of debilitating
chronic pain by reducing OM consumption and its asso-
ciated AEs, as well as improving the quality of life of
those with CMP.
Such an outcome will provide a rationale for incorpor-
ating EA into existing multidisciplinary pain manage-
ment programmes. Future research will examine
whether a different form of EA, such as non-invasive
EA, can be used by patients at home to achieve the same
effectiveness.
Trial status
The trial is open to recruitment and will be completed
by the end of December 2012. We expect the results will
be published by the end of 2013 or early 2014.
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